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Abstract
Background: Recent reports suggest that torasemide might be more beneficial than furosemide in 
patients with symptomatic heart failure (HF). The aim was to compare the effects of torasemide and 
furosemide on clinical outcomes in HF patients.
Methods: This study pilot consisted of data from the ongoing multicenter, randomized, unblinded 
endpoint phase IV TORNADO (NCT01942109) study. HF patients in New York Heart Association 
(NYHA) II–IV class with a stable dose of furosemide were randomized to treatment with equipoten-
tial dose of torasemide (4:1) or continuation of unchanged dose of furosemide. On enrollment and 
control visit (3 months after enrollment) clinical examination, 6-minute walk test (6MWT) and  
assessment of fluid retention by ZOE Fluid Status Monitor were performed. The primary endpoint was  
a composite of improvement of NYHA class, improvement of at least 50 m during 6MWT and decrease 
in fluid retention of at least 0.5 W after 3-months follow-up.
Results: The study group included 40 patients (median age 66 years; 77.5% male). During follow-up 
7 patients were hospitalized for HF worsening (3 in torasemide and 4 in furosemide-treated patients). 
The primary endpoint reached 15 (94%) and 14 (58%) patients on torasemide and furosemide, respec-
tively (p = 0.03).   
Conclusions: In HF patients treated with torasemide fluid overload and symptoms improved more than 
in the furosemide group. This positive effect occurred already within 3-month observation. (Cardiol J  
2019; 26, 6: 661–668)
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Introduction
Heart failure (HF) is one of the leading cardio-
vascular problems in Europe, with a prevalence of 
1–2% in the adult population in developed countr-
ies [1]. Despite an intensive delivery of healthcare 
and education to affected patients, its incidence 
continues to increase, resulting in 50% or greater 
mortality in a 5-year observation [1]. Loop diuret-
ics are cornerstone in the treatment of signs of 
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fluid overload and congestion in patients with HF. 
Despite rapid relief of symptoms in patients with 
acute decompensated HF, long-term use of these 
agents has been consistently associated with ad-
verse events, including electrolyte disturbance, 
activation of the renin–angiotensin–aldosterone 
and the sympathetic nervous systems (RAAS and 
SNS), which could accelerate HF progression [2, 3].
Torasemide and furosemide are representa-
tives of loop diuretics with an identical diuretic 
mechanism, but different pharmacokinetic prop-
erties and additional effects. Compared to furo-
semide, torasemide has greater bioavailability, 
a higher degree of protein binding, and a longer 
half-life. These properties make that torasemide 
works faster, longer and less frequently causes 
rapid micturition than furosemide. Torasemide 
after oral administration is well absorbed from the 
gastrointestinal tract, even in overhydration caused 
by heart, kidney and liver diseases. Moreover, 
torasemide potency is 4 times greater than furose-
mide. Torasemide also has anti-aldosterone activity 
and inhibits myocardial fibrosis and remodeling 
[4–8]. According to previous studies, torasemide 
decreases rates of HF hospitalizations and hospital 
stay, improves exercise tolerance, quality of life, 
left ventricular function, cardiac sympathetic nerve 
activity, myocardial fibrosis, pulmonary congestion, 
peripheral edema, and blood pressure compared 
with furosemide [9–12]. These favorable effects of 
torasemide suggest that this agent would be more 
beneficial than furosemide in patients with HF. 
The main purpose of the present study was 
comparison of the furosemide with torasemide’s 
effects on HF symptoms, including New York 
Heart Association (NYHA) class, fluid retention 
and exercise tolerance in patients with HF.
Methods
Study design
This pilot study consisted of data from the 
ongoing multicenter, randomized, open, phase IV 
TORNADO (TORasemide oN hemodynAmic and 
Neurohormonal Stress, and carDiac remOdeling in 
Heart Failure) study, registered in ClinicalTrials.
gov: NCT01942109. The study was approved by 
a local ethical review board and an informed con-
sent was obtained from each patient. The detailed 
methods and description of the study design have 
been described previously [13]. Briefly, the study 
included patients who were hospitalized in years 
2015–2018 in two cardiology centers in Poland, 
including academic center and a district hospital. 
All patients were diagnosed with HF in NYHA 
II–IV class, irrespective of left ventricular ejec-
tion fraction (LVEF) and treated with optimal HF 
therapy. The diagnosis of HF, according to current 
guidelines [1], was based on clinical (typical HF 
signs and symptoms), echocardiographic and bio-
chemical (increased concentrations of N-terminal 
pro-B-type natriuretic peptide [NT-proBNP] or 
BNP parameters). All demographic, clinical, etiol-
ogy of HF, laboratory data, as well as information 
on medication, were collected. 
Heart failure patients on a stable dose of 
furosemide were randomized to the treatment 
with torasemide or unchanged treatment with 
furosemide (randomization 1:1). After randomiza-
tion, furosemide has been continued in its current 
fixed-dose or was replaced by equipotential dose of 
torasemide (4:1, according to the previous studies 
and manufacturer’s data [6]). Figure 1 shows the 
flow chart of the study design.
Study endpoints
During the baseline hospitalization and on 
control visit (3 months after enrollment) echocar-
diographic examination and 6-minute walk test 
(6MWT) were performed. To assess the level of 
fluid retention, measurement of thoracic base im-
pedance was made using ZOE Fluid Status Monitor. 
The device works in line with principle: the less 
resistance — impedance measured in ohms — the 
more fluid is in the chest. 
In the current analysis the primary endpoint 
was a composite of improvement of NYHA func-
tional class, improvement of at least 50 m during 
6MWT, and decrease of at least 0.5 W in fluid 
retention after 3 months from recruitment. Differ-
ent composite endpoint compared to the initially 
registered endpoints (i.e. events associated with 
HF — deaths, hospitalization) was purposely cho-
sen because of low patient number and one-time 
functional assessment at 3-month follow up.
Statistical analysis 
Continuous and ordinal variables are expressed 
as a median (interquartile range). Categorical data 
were presented as a number of patients and per-
centages. Group comparisons were performed 
using the Fisher exact test for qualitative vari-
ables and t test for quantitative, normally distrib-
uted variables, and the Mann-Whitney U test for 
quantitative, non-normally distributed variables 
(normality of distribution was checked with the 
Shapiro-Wilk test). For all analyses, a p value of less 
than 0.05 was considered statistically significant.
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Results
Baseline characteristics
The current analysis of the TORNADO study 
included 40 patients. During hospitalization, 60% of 
them (n = 24) were randomized to further treatment 
with furosemide and 40% (n = 16) to treatment 
with torasemide. Median age of the study group was 
66 years and 77.5% were male. Mean diuretic dose 
(converted in a ratio of 4:1 on furosemide dose) was 
100 mg and 70 mg in the furosemide and torasem-
ide groups, respectively (p = 0.16). Most common 
etiology of HF was ischemic heart disease (50%). 
Patients in the torasemide and furosemide groups 
were similar in terms of age, gender, chronic dis-
eases, NYHA class, LVEF, heart rate, systolic blood 
pressure, laboratory findings (serum concentrations 
of hemoglobin, creatinine, sodium, potassium, NT-
-proBNP), HF recommended pharmacotherapy (an-
giotensin converting enzyme inhibitor, angiotensin 
receptor blocker, beta-blocker, mineralocorticoid re-
ceptor blocker) and implantable devices (pacemaker, 
cardiac resynchronization therapy, cardioverter 
defibrillator). Baseline characteristics of both study 
groups are presented in Table 1.
Follow-up admission
Patients completed 3-months follow-up. Dur-
ing the follow-up 7 patients were hospitalized for 
HF worsening (3 vs. 4 in torasemide and furosem-
ide groups, respectively). The primary endpoint 
reached 15 (94%) patients of the torasemide group 
and 14 (58%) patients of the furosemide group 
(p = 0.03). The changes in NYHA functional class, 
6MWT and ZOE Fluid Status Monitor test from 
baseline to the end of follow-up are presented 
in the Table 2 and Figures 2–4. During follow-up 
period, an equal percentage of patients treated 
with furosemide and torasemide reached primary 
endpoint in the NYHA class improvement form. 
Torasemide-treated patients were more often, 
but not statistically significant, observed to reach 
primary endpoint as improvement of at least 50 m 
during 6MWT (n = 0.09) or decrease of at least 
0.5 W in fluid retention during 3 months as com-
pared to patients on furosemide (n = 0.51). These 
results reflect a significant decrease in fluid re-
tention and improvement in 6MWT in the whole 
torasemide group as compared to whole furosemide 
group in which increase in fluid retention and de-
terioration in 6MWT was observed.
Figure 1. Flow chart of patient enrollment in the study; CHF — congestive heart failure; NYHA — New York Heart 
Association; 6MWT — six-minute walking test.
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 signed informed consent form—
 age  18 years— ≥
 patients with CHF—
 NYHA functional class IV— II–
 patients who require diuretic therapy—
 stable c inical conditions during therapy— l
 stable cl n cal condit on during index hospitalization— i i i  
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— serum creatinine > 2.5 mg/dL
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Table 1. Comparison of 40 patients with heart failure treated with furosemide or torasemide.
Parameter All patients  
(n = 40)
Furosemide  
(n = 24)
Torasemide  
(n = 16)
P
Demographics
Age [years] 66 [51–81] 65 [58–80] 74 [49–85] 0.29
Gender [male] 31 (77.5) 20 (83.3) 11 (68.8) 0.28
Body mass index [kg/m2] 30 [23–39] 30 [24–39] 30 [20–38] 0.51
Heart failure
Symptoms of HF at admission 12 (30.0) 6 (25.0) 6 (37.5) 0.40
Previous HF hospitalization 25 (62.5) 16 (67.7) 9 (56.3) 0.51
Heart failure etiology:
Ischemic 20 (50.0) 12 (50.0) 8 (50.0) 1.00
Hypertensive 5 (12.5) 2 (8.3) 3 (18.8) 0.33
Dilated cardiomyopathy 7 (17.5) 5 (20.8) 2 (12.5) 0.50
Valve disease 2 (5.0) 2 (8.3) 0 (0.0) 0.24
NYHA [class] 2 [2–3] 2 [2–3] 2 [2–3] 0.94
Ejection fraction [%] 37 [27–52] 35 [29–47] 38 [24–54] 0.93
Medical history
Smoking 20 (50.0) 13 (54.2) 7 (43.8) 0.52
Ischemic heart disease 19 (47.5) 11 (45.8) 8 (50.0) 0.80
Previous CABG/PCI 17 (42.5) 12 (50.0) 5 (31.3) 0.24
Hypertension 23 (57.5) 14 (58.3) 9 (50.0) 0.896
Diabetes 18 (45.0) 12 (50.0) 6 (37.5) 0.44
Dyslipidemia 18 (45.0) 12 (50.0) 6 (37.5) 0.44
Atrial fibrillation 17 (42.5) 9 (37.5) 8 (50.0) 0.58
Cardiac electronic implantable device 17 (42.5) 9 (37.5) 8 (50.0) 0.58
Stroke/TIA 2 (5.0) 2 (8.3) 0 (0.0) 0.27
Peripheral vascular disease 5 (12.5) 3 (12.5) 2 (12.5) 1.00
Chronic kidney disease 14 (35.0) 9 (37.5) 5 (31.3) 0.08
Clinical status
Heart rate [bpm] 75 [60–100] 75 (18.5) 80 [60–100] 0.95
Systolic BP [mmHg] 135 [110–160] 135 [116–160] 133 [100–150] 0.29
Diastolic BP [mmHg] 78 [64–101] 80 [70–101] 70 [60–80] 0.07
Laboratory findings
NT-proBNP [pg/mL] 1681 
[483–5902]
2106 
[656–7032]
1273 
[374–5435]
0.30
Sodium concentration [mmol/L] 141 [137–146] 141 [137–146] 141 [138–144] 0.56
Potassium concentration [mmol/L] 4.4 [3.9–4.9] 4.5 [3.9–4.9] 4.4 [3.9–4.9] 0.86
Creatinine concentration [mg/dL] 1.3 [0.9–1.8] 1.3 [1.0–1.9] 1.2 [0.7–1.6] 0.10
Pharmacotherapy
Beta-blocker 34 (89%) 
N = 38
22 (96%)  
N = 23
14 (93%) 
N = 15
0.76
ACEI 26 (68) 
N = 38
17 (74) 
N = 23
9 (60) 
N = 15
0.37
Angiotensin receptor blocker 7 (18) 
N = 38
2 (8.7) 
N = 23
5 (33) 
N = 15
0.06
Aldosterone antagonist 23 (61) 
N = 38
15 (65) 
N = 23
9 (60) 
N = 15
0.75
Values are showed as median (interquartile range) or number (percentage); ACEI — angiotensin-converting enzyme inhibitor; BP — blood 
pressure; CABG — coronary artery bypass grafting; HF — heart failure; PCI — percutaneous coronary intervention; TIA — transient ischemic 
attack
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Discussion
The results of this study showed that patients 
randomized to torasemide had a higher likelihood 
of reaching the primary composite endpoint of 
improvement of NYHA functional class, decreased 
fluid retention, elongated walking distance com-
pared to patients randomized to furosemide. This 
may indicate that diuretic effect of torsemide com-
pared to furosemide can cause the higher loss of 
body water leading to greater weight loss that can 
facilitate walking. Significant, but not statistically, 
improvement in walking distance and decreased 
fluid retention among torasemide-treated patients 
may be also explained by phenomenon of “regres-
sion to the mean” — which describes the tendency 
of extreme measurement on a first occasion to 
become less extreme when checked again. In this 
study, it was easier for a patient on torasemide to 
have a larger improvement in 6MWT and decrease 
Figure 3. Changes in six-minute walk test (6MWT) from 
baseline to the end of follow-up. The proportion of 
patients with/without improvement in walking distance 
(≥ 50 m) during 6MWT from baseline to the end 
of 3-month follow-up in torasemide-treated patients 
(p = 0.09 compared to furosemide-treated patients).
Figure 2. Changes in New York Heart Association 
(NYHA) functional class from baseline to the end of fol-
low-up. The proportion of patients with/without NYHA 
class improvement (≥ 1 NYHA class) from baseline 
to the end of 3-month follow-up in torasemide-treated 
patients (p = 0.77 compared to furosemide-treated 
patients).
Figure 4. Changes in fluid retention from baseline to the 
end of follow-up. The proportion of patients with/with-
out decrease (≥ 0.5 W) in fluid retention from baseline 
to the end of 3-month follow-up in torasemide-treated 
patients (p  = 0.51 compared to furosemide-treated 
patients).
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Table 2. Changes in the components of the primary from baseline to the end of 3-month follow-up.
Variable Furosemide Torasemide
On  
admission
3-month  
follow up
P On  
admission
3-month  
follow up
P
ZOE® Fluid Status Monitor [Ohm] 17 (15–24) 18 (15–23) 0.68 18 (15–24) 17 (15–19) 0.05
NYHA class 3 (2–3) 2 (1–3) 0.37 3 (2–4) 2 (2–3) 0.18
6MWT [m] 309 (172–450) 320 (120–454) 0.10 243 (120–432) 340 (100–500) 0.29
Values are showed as median (interquartile range); NYHA — New York Heart Association; 6MWT — six-minute walk test
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in fluid retention if the initial walking distance was 
too low and fluid retention was too high.
Recently published data from the QUALIFY 
(QUAlity of adherence to guideline recommen-
dations for Life-saving treatment in HF) survey, 
reported 70% adherence to the guideline-recom-
mended drugs what reflects fairly satisfactory HF 
therapy [14]. The current HF guidelines recom-
mended the use of loop diuretics as a class I indi-
cation to improve symptoms in HF patients with 
both reduced and preserved LVEF [1]. There is no 
clear answer which of the loop diuretics should be 
preferred. The favourable use of furosemide in HF 
might be explained by its early market introduction 
in 1960s, whereas torasemide was approved by 
Food and Drug Administration in 1990s and became 
generic at the beginning of the twenty-first century. 
However, some studies suggest that torasemide 
outperform furosemide’s clinical and economic 
properties by reducing hospital admissions and 
in-hospital stay [15–17].
Furosemide, the most commonly used loop 
diuretic in clinical practice, is known to activate the 
RAAS and the SNS, which could accelerate HF pro-
gression. In contrast to furosemide, torasemide was 
shown to have favorable effect on RAAS inhibition, 
through blockade of the aldosterone receptor [4, 5]. 
Our analysis revealed that torasemide-treated pa-
tients tended to gain more benefits in symptomatic 
HF therapy than furosemide what emphasized the 
importance of obtaining prospective data comparing 
these two loop diuretics.
There are no previous studies showing direct 
comparison of torasemide and furosemide on fluid 
retention. Our study showed more pronounced 
decrease in fluid retention with torasemide than 
furosemide treatment. This probably translated 
into improved NYHA class and elongated walking 
distance in the torasemide group. Recent analysis 
from the Heart Failure Registries of the European 
Society of Cardiology revealed that use of torasem-
ide was associated with significantly lower NYHA 
class comparing to furosemide treatment (p = 
= 0.04). During follow-up torasemide use was associ- 
ated with a lower risk (12.9% vs. 20.0%; p = 0.03) 
of worsening ≥ 1 NYHA functional class (12.9% vs. 
20.0%; p = 0.03) [18]. TORIC (TORasemide In 
Congestive HF) study that revealed significantly 
higher efficiency of torasemide than furosemide 
and other diuretics in functional improving of at 
least 1 grade in NYHA class (45.8% vs. 37.2%; 
p = 0.00017) [19]. It is in line with the metanalysis 
of Kido et al. [20] that showed that torasemide is 
associated with statistically significant improve-
ment in NYHA functional class for patients with HF 
compared with furosemide (p = 0.0004). However, 
torasemide did not provide significant benefits in 
reducing mortality or rehospitalization rates for 
HF (p = 0.15) or cardiovascular disease (p = 0.22) 
compared with furosemide. Moreover, there was 
no significant difference in mortality between tor-
semide and furosemide (p = 0.99). 
According to large international ASCEND-
HF trial, clinicians tend to use torasemide in the 
setting of patients with features of more severe 
disease including refractory volume overload [21]. 
The preferential use of torsemide in these circum-
stances may be related to torasemide’s smaller 
inter- and intraindividual variation in bioavailabil-
ity, longer action increased bioavailability, longer 
half-life and maintained absorption in the setting 
of intestinal edema [6, 21, 22]. Moreover, diuretic 
therapy with torasemide instead of furosemide 
optimizes the quality of daily life of patients with 
HF by reducing number of mictions at 3, 6 and 12 h 
after diuretic intake, and urgency to urinate 
[6, 13, 22]. Other studies have also demonstrated im- 
provement in sympathetic nerve activity as well as 
decreased left ventricle volumes and levels of BNP 
with torsemide compared to furosemide therapy 
[23, 24]. Additional benefits with torsemide over 
furosemide include less urinary potassium loss re-
sulted in reduced arrhythmia burden [25]. In DiNi-
colantonio et al. [7] meta-analysis of randomized 
controlled trials in 471 patients with systolic HF, 
compared with furosemide, torasemide caused 
a 14% reduction in all-cause mortality. It is in line 
with the TOrasemide In Congestive Heart Failure 
(TORIC) study results that reported significantly 
lower mortality in the torasemide (n = 17, 2.2%) 
than in furosemide/other diuretics groups (n = 27, 
4.5%; p < 0.05) [19]. Analysis of the Polish parts of 
Heart Failure Registries of the European Society 
of Cardiology, Pilot and Long-Term, revealed that 
use of torasemide was associated with a significant 
24% risk reduction of the composite endpoint of all-
cause death and hospitalization for worsening HF 
(26.4% vs. 34.7%; p = 0.04). These benefits may 
be due to the additional advantages of torasemide 
such as anti-aldosterone effect [18]. 
Patients discharged after hospitalization for 
HF remain at high risk of death and hospital read-
mission due to recurrence of the symptoms of HF. 
Therefore, every effort should be made to develop 
an optimal treatment strategy in this group of pa-
tients. It is worth mentioning a recently-started 
ToRsemide compArisioN With furoSemide FOR-
Management of Heart Failure (TRANSFORM-HF) 
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study that aim is to compare the effects of furosem-
ide versus torsemide on clinical outcomes over 
12 months in approximately 6000 patients previously 
hospitalized for HF [26].
Limitations of the study
The main limitation of the study is the small 
sample size of the assessed population. The small 
number of participants did not enable assessment 
of the impact of torasemide and furosemide in 
different clinically relevant subgroups i.e. elderly, 
patients with chronic kidney disease, dilated car-
diomyopathy. Noteworthy, the number of patients 
was sufficient to observe differences between the 
effects of torasemide and furosemide on clinical 
outcomes in HF patients. Moreover, the size of 
studied population made it possible to follow all 
subjects closely for the duration of the study and 
gathering considerably detailed information on 
each study participant.
Conclusions
Based on our study, patients randomized to 
torasemide had a higher likelihood of improve-
ment of NYHA functional class, decreased fluid 
retention, elongated walking distance during 
6MWT compared to patients randomized to furo- 
semide entire follow-up period. This may indi-
cate that diuretic effect of torsemide compared 
to furosemide can cause the higher loss of body 
water leading to greater weight loss that can 
facilitate walking. The above results and the 
impact of both drugs on the designed endpoint 
will confirm final results of TORNADO trial with 
the intention of being published by the end of 
2020. However, further large-scale randomized 
trials comparing loop diuretic strategies would 
provide an opportunity to improve HF outcomes 
and reduce health care expenditures with cur-
rently available therapies. 
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